Lexaria's DehydraTECH Technology Shows Enhanced Brain Delivery of Semaglutide in Preclinical Study
TL;DR
Lexaria's DehydraTECH technology delivers semaglutide more effectively to the brain than Rybelsus, potentially offering superior safety and efficacy advantages in GLP-1 drug markets.
Lexaria's DehydraTECH processing enhances brain biodistribution of semaglutide through improved delivery across the blood-brain barrier, as evidenced by fluorescent imaging in rodent studies.
Enhanced brain delivery of GLP-1 drugs could reduce side effects like nausea while improving weight management, making treatments safer and more effective for patients worldwide.
Lexaria's technology shows semaglutide reaching key brain regions at higher levels than conventional formulations, potentially explaining improved drug performance in human trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Lexaria Bioscience Corp. has announced successful results from a preclinical study evaluating the biodistribution of semaglutide, a GLP-1 drug, formulated with its DehydraTECH technology. The study revealed that DehydraTECH-processed semaglutide achieved higher brain biodistribution levels compared to conventional formulations, with the 5mg DehydraTECH composition outperforming the 15mg Rybelsus equivalent in brain fluorescent signal intensity.
The most significant finding was that all tested DehydraTECH doses showed fluorescence above control groups in key brain regions, including the brainstem, paraventricular nucleus of the hypothalamus, and circumventricular organs. These areas are critical for semaglutide's mechanism of action in regulating body weight through GLP-1 receptor activation. Enhanced brain delivery could potentially improve the drug's ability to suppress appetite without causing nausea, addressing one of the most common side effects of current GLP-1 therapies.
John Docherty, Lexaria President and CSO, stated that these findings align with previous rodent studies showing DehydraTECH-processed compounds achieving higher brain levels with superior safety and efficacy. The technology's ability to improve biodistribution may explain the performance benefits observed in Lexaria's human clinical trials, including studies GLP-1-H24-1 and GLP-1-H24-2 available at https://www.lexariabioscience.com.
The study utilized fluorescently tagged semaglutide with cyanine 7 fluorophore for visualization, allowing researchers to track distribution patterns in tissues expressing GLP-1 receptors. Twenty-five Sprague Dawley rats were used, with test articles including vehicle formulations and both DehydraTECH and Rybelsus equivalent compositions. The research was conducted by an independent animal facility specializing in pharmacokinetic evaluations.
These early-stage results suggest that DehydraTECH technology could significantly impact the development of safer and more effective GLP-1 drugs. Improved brain biodistribution may lead to better therapeutic outcomes while reducing side effects, potentially benefiting millions of patients using GLP-1 therapies for weight management and diabetes treatment. Lexaria considers these findings supportive of additional research and potential industry partnerships aimed at advancing next-generation drug delivery solutions.
Curated from NewMediaWire
